NASDAQ:SLRX Salarius Pharmaceuticals (SLRX) Stock Price, News & Analysis → This AI made her leave her job (From Prosper Trading Academy) (Ad) Free SLRX Stock Alerts $3.58 +0.20 (+5.87%) (As of 02:53 PM ET) Add Compare Share Share Today's Range$3.36▼$3.8850-Day Range$0.41▼$0.5452-Week Range$3.09▼$12.48Volume157,941 shsAverage Volume11,198 shsMarket Capitalization$17.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Salarius Pharmaceuticals alerts: Email Address Salarius Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.36Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($26.80) to ($23.50) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.44 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Salarius Pharmaceuticals.Read more about Salarius Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.61% of the float of Salarius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSalarius Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Salarius Pharmaceuticals has recently decreased by 18.51%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSalarius Pharmaceuticals does not currently pay a dividend.Dividend GrowthSalarius Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SLRX. Previous Next 2.4 News and Social Media Coverage News SentimentSalarius Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Salarius Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest2 people have searched for SLRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Salarius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.50% of the stock of Salarius Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 11.88% of the stock of Salarius Pharmaceuticals is held by institutions.Read more about Salarius Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Salarius Pharmaceuticals are expected to grow in the coming year, from ($26.80) to ($23.50) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Salarius Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Salarius Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSalarius Pharmaceuticals has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Salarius Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading AcademyThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and finds hot stocks that you probably have never even heard of… …it recommends the best potential strategy to use on the names it finds (with historical data to prove it)Click Here To Read More About This Game Changing AI Tool About Salarius Pharmaceuticals Stock (NASDAQ:SLRX)Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.Read More SLRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SLRX Stock News HeadlinesJune 16 at 9:56 AM | americanbankingnews.comShort Interest in Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Drops By 18.5%June 13, 2024 | americanbankingnews.comSalarius Pharmaceuticals Stock Scheduled to Reverse Split on Monday, June 17th (NASDAQ:SLRX)June 13, 2024 | americanbankingnews.comSalarius Pharmaceuticals (NASDAQ:SLRX) Shares Scheduled to Reverse Split on Monday, June 17thJune 12, 2024 | globenewswire.comSalarius Pharmaceuticals Announces 1-for-8 Reverse Stock SplitMay 14, 2024 | investorplace.comSLRX Stock Earnings: Salarius Pharmaceuticals Beats EPS for Q1 2024April 2, 2024 | finance.yahoo.comSLRX Pursues Important GoalMarch 27, 2024 | msn.comWall Street Set to Open Modestly Lower Monday Ahead of Housing, Inflation DataMarch 25, 2024 | msn.comWhy Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving PremarketMarch 23, 2024 | finanznachrichten.deSalarius Pharmaceuticals, Inc.: Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 22, 2024 | sfgate.comSalarius: Q4 Earnings SnapshotMarch 22, 2024 | globenewswire.comSalarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 5, 2024 | msn.comQuoin stock craters 47% on public offering after rallying in prior sessionMarch 4, 2024 | msn.comQuoin stock soars 60% on FDA update for ichthyosis drugFebruary 22, 2024 | markets.businessinsider.comSalarius Pharmaceuticals Implements Cost-savings MeasuresFebruary 22, 2024 | msn.comSalarius's CEO David Arthur steps downFebruary 22, 2024 | finance.yahoo.comSalarius Provides Update on Strategic Review Process and Plans to Support Ongoing Seclidemstat Clinical Trials by Further Reducing ExpensesFebruary 9, 2024 | uk.investing.comSalarius Pharmaceuticals Inc (SLRX)January 16, 2024 | finance.yahoo.comSalarius Pharmaceuticals Issued U.S. Patent for Next-Generation Targeted Protein DegradersJanuary 13, 2024 | wsj.comSquare Pharmaceuticals Ltd.January 3, 2024 | finance.yahoo.comInvestigator-initiated Phase 1/2 Clinical Trial Using Salarius Pharmaceuticals’ Seclidemstat in Combination with Azacitidine to Treat Hematologic Cancers Resumes Patient EnrollmentNovember 10, 2023 | finance.yahoo.comSLRX Continues Work as it Seeks AlternativesNovember 8, 2023 | morningstar.comSalarius Pharmaceuticals Inc SLRXNovember 7, 2023 | finance.yahoo.comSalarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development ProgramAugust 10, 2023 | bizjournals.comSalarius Pharmaceuticals cuts half of workforce despite positive clinical developmentsAugust 10, 2023 | finance.yahoo.comSalarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business UpdateSee More Headlines Receive SLRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Salarius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SLRX CUSIPN/A CIK1615219 Webwww.salariuspharma.com Phone(832) 834-6992FaxN/AEmployees2Year Founded2011Profitability EPS (Most Recent Fiscal Year)($2.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,540,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-152.20% Return on Assets-111.71% Debt Debt-to-Equity RatioN/A Current Ratio3.91 Quick Ratio3.91 Sales & Book Value Annual Sales$1.84 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.34 per share Price / Book0.32Miscellaneous Outstanding Shares4,780,000Free Float4,609,000Market Cap$2.02 million OptionableNot Optionable Beta1.03 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. David J. Arthur M.B.A. (Age 61)CEO, President & Director Comp: $343.2kMr. Mark J. Rosenblum CPA (Age 71)Executive VP of Finance & CFO Key CompetitorsMedAvailNASDAQ:MDVLSonoma PharmaceuticalsNASDAQ:SNOAPhio PharmaceuticalsNASDAQ:PHIOUniverse PharmaceuticalsNYSE:UPCGraybug VisionNASDAQ:GRAYView All Competitors SLRX Stock Analysis - Frequently Asked Questions Should I buy or sell Salarius Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Salarius Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" SLRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLRX, but not buy additional shares or sell existing shares. View SLRX analyst ratings or view top-rated stocks. How have SLRX shares performed in 2024? Salarius Pharmaceuticals' stock was trading at $5.20 at the beginning of the year. Since then, SLRX shares have decreased by 31.3% and is now trading at $3.57. View the best growth stocks for 2024 here. Are investors shorting Salarius Pharmaceuticals? Salarius Pharmaceuticals saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 27,300 shares, a decrease of 18.5% from the May 15th total of 33,500 shares. Based on an average daily volume of 113,600 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.6% of the shares of the company are short sold. View Salarius Pharmaceuticals' Short Interest. When is Salarius Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our SLRX earnings forecast. How were Salarius Pharmaceuticals' earnings last quarter? Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) released its earnings results on Monday, May, 13th. The company reported ($3.28) earnings per share for the quarter, topping analysts' consensus estimates of ($53.60) by $50.32. What ETF holds Salarius Pharmaceuticals' stock? Horizon Kinetics Medical ETF holds 31,094 shares of SLRX stock, representing 0.08% of its portfolio. When did Salarius Pharmaceuticals' stock split? Salarius Pharmaceuticals shares reverse split on Monday, June 17th 2024. The 1-8 reverse split was announced on Monday, June 17th 2024. The number of shares owned by shareholders will be adjusted after the market closes on Monday, June 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. What other stocks do shareholders of Salarius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Salarius Pharmaceuticals investors own include Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Arbutus Biopharma (ABUS), Fulcrum Therapeutics (FULC), Allena Pharmaceuticals (ALNA), Biocept (BIOC), DURECT (DRRX), Dynavax Technologies (DVAX) and TG Therapeutics (TGTX). How do I buy shares of Salarius Pharmaceuticals? Shares of SLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SLRX) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredThis AI made her leave her jobThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe Scary Fed Idea To Turn Your Dollars Into a Digital Power GrabCash is becoming a relic of the past… Soon, Biden and the Federal Reserve plan to replace the dollar with t...Oasis Gold | SponsoredBill Clinton Backing Biden Replacement???Do you want to see who I believe will be the next president of the U.S.A? It won’t be Biden…And it won’t be...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Salarius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Salarius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
